April has been opened, and the new pharmaceutical industry trends have been sorted out!

[China Pharmaceutical network industry trends] in the past three months, Chinese pharmaceutical enterprises have made new changes in personnel changes, financing and new drug research and development For example, the resignation of general manager of Harbin Pharmaceutical Co., Ltd., the submission of new drug listing application by PetroChina, the proposed IPO of new sharp to raise US $100 million, the completion of round C financing of US $70 million by Yifang biology, and the entry of Wuhan Keqian biology and Anhan Technology (Wuhan) into the list of the first batch of scientific and technological innovation enterprises, etc Now, it has set sail in April, and in less than a week, there have been several major events in the pharmaceutical industry that have attracted the attention of the industry In this regard, the author makes a brief review Yaoming biology will promote the production of Sanyin breast cancer drugs On April 9, Yaoming biology released a notice saying that Yaoming biology will cooperate with NBE therapeutics, a Swiss innovative biomedical enterprise The two sides will establish a comprehensive cooperation in the development and production of nbe-002, an ADC product of NBE therapeutics It is reported that the nbe-002 project is a potential immunoactive antibody coupling drug for cancer target ror1 According to Yao Ming, the antibody coupling drug is mainly used to treat Sanyin breast cancer and other solid tumors It is expected to enter clinical trials in 2020 Novo Nordisk appointed Tang Xingbin as vice president of Commerce Department On April 8, Novo Nordisk announced that Tang Xingbin was appointed as vice president of Commerce Department of Novo Nordisk in Greater China, reporting to Zhou Xiaping, vice president and President of Greater China of Novo Nordisk, base Beijing, effective from April 16 It is reported that before joining Novo Nordisk, Tang Xingbin worked in MSD for 16 years On May 9, 2017, personnel adjustment occurred in MSD China, and Tang Xingbin was transferred to MSD global vaccine department to serve as regional marketing director (RML) of global vaccine China, with specific responsibilities for local implementation of global vaccine strategy and support for China's vaccine business The organizational structure of Takeda China was basically established On April 4, Shan Guohong, President of Takeda China, announced to employees the organizational structure adjustment and personnel appointment within each Bu in China, including the integration of digestion and internal medicine team, tumor, blood and immune team of Hong Kong business department In addition, in order to launch the new products in the Chinese market, the medical affairs department has also integrated multiple treatment areas, expanded the functions of the team, renamed the medical information and communication team to provide innovative medical information services for internal and external customers, and established a full-time Hong Kong Medical Affairs team According to the industry, the move means that the Takeda pharmaceutical and Takeda China's organizational structure have been basically established after the acquisition in January this year 18 vaccine products of Changchun Changsheng were cancelled On April 4, the State Drug Administration issued the announcement on canceling 85 drug approval numbers such as ferritin radioimmunoassay kit (No 29, 2019), and canceling 85 drug approval numbers such as ferritin radioimmunoassay kit, involving 22 enterprises such as Changchun Changsheng, China Resources Sanjiu and Hainan pharmaceutical It is worth noting that in the list of cancelled drug approval numbers disclosed in this disclosure, 19 drug approval numbers were cancelled because the enterprise was revoked the drug production license according to law, and these 19 products are all from Changchun Changsheng Aberdeen will cut 178 jobs Recently, foreign media reported that Aberdeen will cut 178 jobs from stemcentrx in San Francisco According to the data, Aberdeen spent $5.8 billion to acquire stemcentrx and its experimental cancer candidate drug, but terminated the phase III survival trial of the star rova-t of stemcentrx in December 2018 In early 2019, aberway recorded about $4 billion in impairment charges related to the retirement of its rova-t development According to the documents submitted by warn, the downsizing of stemcentrx will start on April 5 These 178 positions are classified as "sexual layoffs", at which time nearly 74% of employees will be laid off.